[The neuropharmacology of beta adrenolytics].
The paper provides a survey of neuropharmacological fundamentals for the use of beta-adrenolytics in the treatment of psychiatric and neurological diseases. In particular there are discussed results of animal- and clinical-pharmacological experiments carried out in order to assess the influence of betaadrenolytics in disorders and diseases such as anxiety, psychoses, tremor, some kinds of addiction, migraine and epilepsy. The conclusion is that in spite of some ascertained clinical indications on the one hand and a variety of neuropharmacological results on the other the mode of action of betaadrenolytics at the level of the CNS remains still insufficiently explainable.
Lasek
R
R
Müller
M
M
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000818:Animals; D001921:Brain / Q000187:drug effects*; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D008881:Migraine Disorders / Q000188:drug therapy; D019965:Neurocognitive Disorders / Q000188:drug therapy; D018377:Neurotransmitter Agents / Q000378:metabolism; D011433:Propranolol / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D019966:Substance-Related Disorders / Q000188:drug therapy
D000318:Adrenergic beta-Agonists; D018377:Neurotransmitter Agents; D011943:Receptors, Adrenergic, beta; D011433:Propranolol
Zur Neuropharmakologie von Betaadrenolytika.